

www.deltacure2026.com
also online 

Chairs:
Pietro Lampertico
and **Heiner Wedemeyer**

Delta *cure*

5th International Meeting

scientific program



OCTOBER 15-16 2026 MILAN, ITALY

with the endorsement of



UNIVERSITÀ
DEGLI STUDI
DI MILANO



Endorsed



Fondazione IRCCS Ca' Granda
Ospedale Maggiore Policlinico

Sistema Socio Sanitario



Regione
Lombardia



Dear Colleagues and Friends!

It is our great pleasure to welcome you to the **5th Edition of Delta Cure International Meeting**, taking place in **Milan on October 15th-16th 2026**.

Recognized as the leading international forum fully dedicated to **Hepatitis Delta Virus**, Delta Cure continues to bring together leading experts, clinicians, and researchers from around the world.

Since its beginning, this meeting has played a central role in advancing the collective understanding of this uniquely severe and challenging form of viral hepatitis. The 2026 scientific program will once again offer a comprehensive exploration of the virus, spanning **epidemiology, virology, immunology, clinical progression**, and the **long-term complications** associated with chronic infection.

For the first time, the abstracts accepted for the Delta Cure 2026 edition will be published in a **dedicated supplement of the indexed journal *BMJ Open Gastroenterology***, further enhancing the visibility and impact of the scientific contributions presented at the meeting.

We remain strongly committed to supporting the next generation of HDV and HBV researchers: a substantial part of the program will be dedicated to **oral abstract presentations by early-career investigators**, alongside expert-led poster tours, fostering meaningful engagement and facilitating their integration into the international research community.

We look forward to welcoming you to **Milan** in October 2026 for what promises to be another stimulating and **impactful Delta Cure Meeting**.

With warm regards,

The Chairs
Pietro Lampertico and Heiner Wedemeyer



Chairs

Pietro Lampertico - Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan (Italy)

Heiner Wedemeyer - Hannover Medical School, Hannover (Germany)

Scientific Advisors

Elisabetta Degasperi - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Lisa Sandmann - Hannover Medical School, Hannover (Germany)

Kosh Agarwal - King's College Hospital, London (UK)

Alessio Michele Aghemo - IRCCS Humanitas Research Hospital, Milan (Italy)

Soo Aleman - Infectious Diseases, Karolinska University Hospital, Stockholm (Sweden)

Lena Allweiss - University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

Maria Paola Anolli - Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan (Italy)

Tarik Asselah - Hôpital Beaujon, University of Paris, Paris (France)

Annalisa Berzigotti - University of Bern, Bern (Switzerland)

Maurizia Rossana Brunetto - Azienda Ospedaliero Universitaria Pisana, Università degli Studi di Pisa, Pisa (Italy)

Patrizia Burra - Azienda Ospedaliera Università di Padova, Padua (Italy)

María Buti - Hospital General Universitari Valle Hebron, Barcelona (Spain)

Mariana Cardoso - Centro Hospitalar Universitário de Lisboa Central, Lisbon (Portugal)

Ivana Carey - King's College Hospital NHS Foundation Trust, London (UK)

Gian Paolo Caviglia - Università degli Studi di Torino, Turin (Italy)

Carla Coffin - Viral Hepatitis Clinic, Calgary Liver Unit, Division of Gastroenterology and Hepatology, Department of Medicine, Snyder Institute, Cumming School of Medicine, University of Calgary, Calgary (Canada)

Maura Dandri - University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

FACULTY

Elisabetta Degasperi - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Rafael Esteban - Hospital Universitario Val d'Hebron, Universidad Autonoma de Barcelona, Barcelona (Spain)

Ohad Etzion - Soroka University Medical Center, Beersheba (Israel)

Liana Gheorghe - Fundeni Clinical Institute, Bucharest (Romania)

Saeed Hamid - The Aga Khan University, Karachi (Pakistan)

Mathias Jachs - Medical University of Vienna, Vienna (Austria)

Helenie Kefalakes - Hannover Medical School, Hannover (Germany)

Patrick Kennedy - Queen Mary University of London, London (UK)

Tatyana Kushner - Institute for Liver Medicine, New York (USA)

Sabela Lens - Hospital Clínic Barcelona, Barcelona (Spain)

Olufunmilayo Lesi - World Health Organization, Geneva (Switzerland)

Massimo Levrero - IHU Lyon - Institute of Hepatology of Lyon, Lyon (France)

Maëlle Locatelli - Hospital Clínic Barcelona, Barcelona (Spain)

Julie Lucifora - International Center for Infectiology Research, Lyon (France)

George Papatheodoridis - Gastroenterology, Hepatology and Liver Transplantation, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens (Greece)

Nancy Reau - Rush University Medical Center, Chicago (USA)

Thomas Reiberger - Medical University of Vienna and Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna (Austria)

Lisa Sandmann - Hannover Medical School, Hannover (Germany)

Milan Sonneveld - Erasmus MC University Medical Center, Rotterdam (Netherlands)

Christiane Stern - Centre Hospitalier de Versailles, Paris (France)

Camille Sureau - Université de Tours, Tours (France)

Norah Terrault - Keck Medical Center of USC, Los Angeles (USA)

Barbara Testoni - The Lyon Hepatology Institute, Lyon (France)

Stephan Urban - Heidelberg University Hospital, Heidelberg (Germany)

Robert Wong - Stanford University School of Medicine, Stanford (USA)

Zobair M. Younossi - Chairman, Global NASH/MASH Council; Center for Outcomes Research in Liver Diseases; Global Center for Liver Outcomes & Policy Research, Georgetown University School of Medicine, Washington DC (USA)



OCTOBER 15, 2026

11.00-11.15 Welcome by the Chairs *P. Lampertico and H. Wedemeyer*

SESSION 1

Bookmarks and Epidemiology

Chairs: S. Hamid and O. Lesi

11.15-11.30 Bookmarks in HDV: a 2025/2026 overview *L. Sandmann*

11.30-11.45 Epidemiology of HDV in Low to Middle IC: WHO perspectives *O. Lesi*

11.45-12.00 Epidemiology of HDV in US: still a black box? *R. Wong*

12.00-12.10 ORAL PRESENTATION 1

High prevalence of HDV and HBV detected amongst household contacts of HDV positive individuals in rural Sindh *S.S. Hamid*

12.10-12.45 Panel discussion *Chairs and Speakers*

12.45-13.45 Lunch

SESSION 2

Pathophysiology: Virology and Immunology

Chairs: M.R. Brunetto and S. Urban

13.45-14.00 Virology update *J. Lucifora*

14.00-14.15 Immunology update: lessons learned from liver spatial transcriptomics *M. Locatelli*

14.15-14.25 ORAL PRESENTATION 2

Paired liver and serum deep sequencing reveals differences between circulating HDV and intrahepatic viral populations *J. Ringlander*

14.25-14.35 ORAL PRESENTATION 3

Identification of GBP3 as a novel host factor required for Hepatitis Delta Virus recognition by hepatocytes *R. Fouille*

14.35-14.50 Poster summaries 1 *L. Allweiss*

14.50-15.20 Panel discussion *Chairs, Speakers and H. Kefalakes*

OCTOBER 15, 2026

15.20-16.20 **Coffee break and Poster Session No. 1 with guided Poster Tour**
M. Sonneveld and C. Stern

SESSION 3

Diagnostics and Natural History

Chairs: K. Agarwal and M. Dandri

16.20-16.35 **Diagnostics update** *M.P. Anolli*

16.35-16.50 **HCC in HDV patients: pathogenesis, incidence and predictors** *G. Papatheodoridis*

16.50-17.00 **ORAL PRESENTATION 4**

Quantitative anti-HDV measurement as a diagnostic surrogate of HDV replication *E. Dileo*

17.00-17.10 **ORAL PRESENTATION 5**

Predictors of advanced chronic liver disease (ACLD) in patients with Hepatitis Delta Virus (HDV) infection: does the genotype matter?
M. Cardoso

17.10-17.25 **Poster summaries 2** *I. Carey*

17.25-17.55 **Panel discussion** *Chairs, Speakers and M. Levrero*

17.55-19.00 **Presentation of Delta Cure 2026 Awardee**

Chairs: P. Lampertico and H. Wedemeyer

Distinguished Lecture *C. Sureau*

19.00-19.05 **Day 1 closing**

P. Lampertico and H. Wedemeyer



OCTOBER 16, 2026

SESSION 4

Current treatment options

Chairs: R. Esteban and L. Gheorghe

- 08.30-08.45 BLV in clinical trials: filling the gaps (a debate) *M. Buti and N. Reau*
- 08.45-09.00 Long-term outcomes in BLV-treated patients *E. Degasperi*
- 09.00-09.10 ORAL PRESENTATION 6
Clinical and economic value of early treatment with bulevirtide in chronic Hepatitis Delta Virus *R. Dominguez*
- 09.10-09.20 ORAL PRESENTATION 7
Hepatic recompensation according to Baveno VII in decompensated chronic Hepatitis Delta treated with bulevirtide: a multicenter experience *M. Meszaros*
- 09.20-09.30 ORAL PRESENTATION 8
Predicting time to cure in HDV patients treated with bulevirtide and pegylated interferon-alpha in the SEE-D trial *H. Dahari*
- 09.30-09.45 Poster summaries 3 *M. Jachs*
- 09.45-10.15 Panel discussion *Chairs and Speakers*
- 10.15-11.15 Coffee break and Poster Session No. 2 with guided Poster Tour
M. Cardoso and G.P. Caviglia

SESSION 5

Treatment options in clinical development

Chairs: T. Asselah and S. Lens

- 11.15-11.30 Anti-HBs monotherapies: results of phase II/III studies *T. Kushner*
- 11.30-11.45 Anti-HBs and siRNA combination: results of phase II/III studies *P. Kennedy*
- 11.45-12.00 Other therapeutic approaches for HDV in phase I /II/III *S. Aleman*
- 12.00-12.10 ORAL PRESENTATION 9
Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic Hepatitis Delta: phase 3 D-LIVR trial *N. Reau*

OCTOBER 16, 2026



12.10-12.20 ORAL PRESENTATION 10
The efficacy and safety of siRNA ozisiran in patients with chronic Hepatitis D:
Interim results through treatment Week 36 from the phase 2a RC04T001 trial
K. Lindahl

12.20-12.35 ASO-based phase III studies in HBV: any relevance for HDV? *N. Terrault*

12.35-13.05 Panel Discussion *Chairs, Speakers, O. Etzion and B. Testoni*

13.05-14.00 Lunch

SESSION 6

Unmet needs in Hepatitis Delta

Chairs: C. Coffin and T. Reiberger

14.00-14.15 BAVENO VIII update: any change for HDV patients? *A. Berzigotti*

14.15 -14.30 Liver transplantation for HDV: time for HBIG-free regimens? *P. Burra*

14.30-14.45 The impact of MASH/MASLD in HBV and HDV: metHBV and metHDV? *Z. Younossi*

14.45-15.15 Panel discussion *Chairs, Speakers and A.M. Aghemo*

15.15-15.50 Roundtable discussion

Chairs: P. Lampertico and H. Wedemeyer

Academia, Pharma, Diagnostics, Patient Associations

15.50-16.00 Closing Remarks and farewell
P. Lampertico and H. Wedemeyer



Meeting Information

The Meeting will be streamed live on Zoom.

CONGRESS VENUE

Fondazione Cariplo Conference Center

Via Romagnosi, 8 - 20121 Milan, Italy

OFFICIAL LANGUAGE

English, no simultaneous translation provided

CME ACCREDITATION

The meeting has been accredited to the Italian Ministry of Health - 150- 488154 - for 14 CME credits for the following disciplines: Physicians: Allergology and Clinical Immunology; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical Pathology; Hygiene, Epidemiology and Public Health; Hospital Medical Direction; Epidemiology.

To obtain Italian CME credits participants must attend at least 90% of sessions and respond correctly to at least 75% of the questions included in the final evaluation questionnaire that will be available on-line from October 17th to October 19th (only one attempt allowed).

ETHICAL MEDTECH ACCREDITATION

The meeting has been assessed "Compliant" by MedTech Europe (EMT-26-09659).

CME PROVIDER & PCO

Effetti srl

Via G.B. Giorgini 16 - 20151 Milan, Italy

Tel. +39 02 3343281

E-mail: deltacure2026@effetti.it

www.deltacure2026.com



Delta*cure*

5th International Meeting

Congress venue:
Fondazione Cariplo
Conference Center
Via Romagnosi, 8
20121 Milan, Italy

CME Provider & PCO
Effetti srl
Via G.B. Giorgini 16 - 20151 Milan, Italy
Tel. +39 02 3343281
E-mail: deltacure2026@effetti.it

OCTOBER 15-16 2026 MILAN, ITALY



www.deltacure2026.com